Merck & Co. (NYSE: MRK) recently received a number of ratings updates from brokerages and research firms:

  • 9/14/2016 – Merck & Co. had its “buy” rating reaffirmed by analysts at Argus. They now have a $65.00 price target on the stock.
  • 9/13/2016 – Merck & Co. was given a new $60.00 price target on by analysts at Morgan Stanley. They now have a “hold” rating on the stock.
  • 9/12/2016 – Merck & Co. had its “hold” rating reaffirmed by analysts at Jefferies Group. They now have a $56.00 price target on the stock, down previously from $57.00.
  • 9/11/2016 – Merck & Co. had its “hold” rating reaffirmed by analysts at Berenberg Bank. They now have a $62.00 price target on the stock.
  • 9/9/2016 – Merck & Co. had its price target raised by analysts at Barclays PLC from $66.00 to $72.00. They now have an “overweight” rating on the stock.
  • 8/11/2016 – Merck & Co. had its “outperform” rating reaffirmed by analysts at Sanford C. Bernstein. They now have a $74.00 price target on the stock, up previously from $66.00.
  • 8/10/2016 – Merck & Co. had its “neutral” rating reaffirmed by analysts at Citigroup Inc.. They now have a $65.00 price target on the stock.
  • 8/8/2016 – Merck & Co. had its price target raised by analysts at Jefferies Group from $53.00 to $57.00. They now have a “hold” rating on the stock.
  • 8/8/2016 – Merck & Co. had its price target raised by analysts at Deutsche Bank AG from $58.00 to $59.00. They now have a “hold” rating on the stock.
  • 8/8/2016 – Merck & Co. had its “neutral” rating reaffirmed by analysts at Piper Jaffray Cos.. They now have a $62.00 price target on the stock, up previously from $58.00.
  • 8/7/2016 – Merck & Co. was upgraded by analysts at Credit Suisse Group AG from a “neutral” rating to an “outperform” rating. They now have a $73.00 price target on the stock, up previously from $62.00.
  • 8/5/2016 – Merck & Co. was upgraded by analysts at BMO Capital Markets from a “market perform” rating to an “outperform” rating. They now have a $72.00 price target on the stock, up previously from $62.00.
  • 8/2/2016 – Merck & Co. had its “market perform” rating reaffirmed by analysts at BMO Capital Markets. They now have a $62.00 price target on the stock.

Shares of Merck & Co. (NYSE:MRK) opened at 61.94 on Wednesday. Merck & Co. has a 12-month low of $47.97 and a 12-month high of $64.00. The stock has a market cap of $171.28 billion, a PE ratio of 33.98 and a beta of 0.63. The stock’s 50 day moving average is $62.42 and its 200-day moving average is $57.54.

Merck & Co. (NYSE:MRK) last released its earnings results on Friday, July 29th. The company reported $0.93 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.91 by $0.02. The firm earned $9.84 billion during the quarter, compared to analyst estimates of $9.79 billion. Merck & Co. had a net margin of 13.01% and a return on equity of 23.41%. The business’s revenue was up .6% on a year-over-year basis. During the same quarter last year, the business earned $0.86 EPS. Equities analysts expect that Merck & Co. will post $3.75 EPS for the current year.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/21/research-analysts-weekly-ratings-updates-for-merck-co-mrk.html

The company also recently announced a quarterly dividend, which will be paid on Friday, October 7th. Stockholders of record on Thursday, September 15th will be issued a $0.46 dividend. The ex-dividend date of this dividend is Tuesday, September 13th. This represents a $1.84 annualized dividend and a dividend yield of 2.97%. Merck & Co.’s dividend payout ratio (DPR) is presently 101.10%.

In other news, EVP Adam H. Schechter sold 50,000 shares of the firm’s stock in a transaction dated Friday, July 1st. The shares were sold at an average price of €57.69 ($64.10), for a total value of €2,884,500.00 ($3,205,000.00). Following the completion of the sale, the executive vice president now owns 50,000 shares in the company, valued at approximately €2,884,500 ($3,205,000). The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Adam H. Schechter sold 39,200 shares of the firm’s stock in a transaction dated Thursday, September 1st. The stock was sold at an average price of €62.61 ($69.57), for a total transaction of €2,454,312.00 ($2,727,013.33). Following the completion of the sale, the executive vice president now owns 39,200 shares of the company’s stock, valued at approximately €2,454,312 ($2,727,013.33). The disclosure for this sale can be found here. 0.05% of the stock is currently owned by insiders.

Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products, which it markets directly and through its joint ventures. It operates through one segment, Pharmaceutical. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.

5 Day Chart for NYSE:MRK

Receive News & Ratings for Merck & Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co and related companies with MarketBeat.com's FREE daily email newsletter.